Prostaglandin analogs in ophthalmology.
| Autor: | Subbulakshmi S; Department of Glaucoma, Aravind Eye Hospital, Puducherry, India., Kavitha S; Department of Glaucoma, Aravind Eye Hospital, Puducherry, India., Venkatesh R; Department of Glaucoma, Aravind Eye Hospital, Puducherry, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of ophthalmology [Indian J Ophthalmol] 2023 May; Vol. 71 (5), pp. 1768-1776. |
| DOI: | 10.4103/IJO.IJO_2706_22 |
| Abstrakt: | Glaucoma is a major cause of irreversible blindness worldwide. Reducing intraocular pressure (IOP) is currently the only approach to prevent further optic nerve head damage. Pharmacotherapy is the mainstay of treatment for glaucoma patients. In recent years, a significant milestone in glaucoma treatment has been a transition to prostaglandin analogs (PGAs) as the first line of drugs. The rapid shift from traditional β-blockers to PGAs is primarily due to their excellent efficacy, convenient once-a-day usage, better diurnal control of IOP, and systemic safety profiles. This review article aims to provide information regarding the various PGAs in practice and also the newer promising drugs. Competing Interests: None |
| Databáze: | MEDLINE |
| Externí odkaz: |
|